Эффективность и безопасность химерных моноклональных антител к ФНО альфа при ювенильном анкилозирующем спондилите
Диссертация
У больных ювенильным анкилозирующим спондилитом с поражением позвоночника химерные моноклональные антитела оказывают терапевтическое влияние на активность суставного синдрома и аксиальные проявления болезни. Через неделю у этого контингента больных активность болезни по индексу ВАЗБА! снизилась в 2 раза, выраженность, функциональной недостаточности по индексу ВА8Р1 — в 10 раз, ригидность… Читать ещё >
Список литературы
- Агабабова Э.Р., Годзенко A.A., Гусева И. А., Гусейнов Н. И., Крылов М. Ю., Эрдес Ш:Ф. Анкилозирующий спондилоартрит и другие спондилоартриты: современное состояние проблемы и вопросы классификации // Клиническая ревматология, 1997. № 1. С. 2−8.
- Алексеева A.M. Эффективность и безопасность блокатора ФНО-альфа инфликсимаба у больных ювенильным ревматоидным артритом // Автореф. Дисс.. .канд.мед.наук — М. — 2008. —23с.
- Алексеева Е.И. Ревматические болезни и их влияние на качество жизни детей и их семей. Качество жизни. Медицина. — 2008. — С. 14−17
- Анселл Б.М. Ревматические болезни у детей: Пер. с англ.—М., 1983, 248с.
- Бадокин B.C. Эффективность ингибиторов биологического ответа при псориатическом артрите // Врач. —2005−5:48−52.
- Баранов A.A., Алексеева Е. И. Ревматические болезни у детей: проблемы и пути их решения//Вопр. совр. педиат. 2004- 3 (1): 7−11.
- Бехтерев В.М. Одеревенелость позвоночника с искривлением его, как особая форма заболевания //Врач, 1892. Т. 13. N36. С. 899−903.
- Бочкова А.Г. Анкилозирующий спондилит. М.: Институт ревматологии РАМН, 2005. — С. 3—26.
- Гусейнов Н.И. Анкилозирующий спондилоартрит: особенности патогенеза, клиника, эволюция и прогноз различных клинических форм: Автореф. Дисс. доктора мед. наук. М., 1990.
- Ковальчук Г. Г., Артрит при болезни Бехтерева у детей и подростков: Диссертация канд.мед.наук.—М., 1989.—119с.
- Кузьмина H.H. Проблема ювенилъных спондилоартропатий на современном этапе // Детская ревматология, 1997. № 5. С. 25−29.
- Кузьмина Н. Н: Ювенильный анкил озирующий спондилоартрит. Детская ревматология: Руководство для врачей / Под ред. A.A. Баранова, ЛЖ. Баженовой: —Mi: Медицина- 2002: С. 141−182.
- Кузьмина:! Н. Н, Никишина^ ИГЛ Комплексная? терапиям ювенильных? спондилоартритов: алгоритм лечебной программы // Международныйжурнал практики- 2000. 4. С. 7−8.
- Марканова А.М. Сравнительная эффективность сульфасалазииа и низких доз? метотрексата в лечение больных олигоартикулярным вариантом ювенильного ревматоидного артрита.//Автореф. Дис. .канд. мед.наук.-— Москва—2001.- с.24
- Марканова А. М,. Шахбазян И. Е., Алексеева Е. И. Эффективность сульфасалазииа и низких доз! метотрексата у детей- страдающих олигоартикулярным вариантом ювенильного ревматоидного: артрита // Российский педиатрический журнал. — 2001−4:34−37.
- Насонов Е.Л. Сульфасалазин: перспективы применения в ревматологии.// Клиническая медицина-- 1997. № 6- - с.39−44.
- Никишина- И. П. Ювенильный анкилозирующий спондилоартрит. Практическое руководство по детским болезням. Том III / Под общей ред. В. Ф. Коколиной, А. Г. Румянцева. — М.: Медпрактика, 2004- С. 620−649.
- Никишина И.П.. Ювенильный анкилозирующий? спондилоартрит: клиника и особенности течения.//Автореф. Дисс.. .канд.мед.наук М. -1995.-25с.
- Чепой В.М. Воспалительные и дегенеративные заболевания позвоночника.—М.:1978.—283с.
- Шарапова О.В., Корсунский A.A. Совершенствование медицинской помощи детям, страдающим ревматическими болезнями. //Вопр. совр. педиат. 2004- 3 (1): 12−5.
- Яковлева A.A. Анкилозирующий спондилоартрит (Болезнь Бехтерева) у детей и подростков. Бишкек: Госконцерн «Учкун», 1996. 160 с.
- Яковлева A.A. Анкилозирующий спондилоартрит у детей и подростков.//Ревматология.—1991 — № 2 с.31−38.
- Althoff СЕ, Appel Н, Rudwaleit М, Sieper J, Eshed I, Hamm В, et al. Whole-body MRI as a new screening tool for detecting axial and peripheral manifestations of spondylarthritis. Ann Rheum Dis 2007−66:983−5.
- Amos RS, Pullar T, Bax DE, Situnayake D, Capell HA, McConkey B. Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years.//Br Med J (Clin Res Ed). 1986 Aug 16−293(6544):420−3.
- Appel H, Loddenkemper С, Grozdanovic Z, Ebhardt H, Dreimann M, Hempfing A, et al. Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis. Arthritis Res Ther 2006−8:R143.
- Arnett F.C. The seronegative spondyloarthropathies.//Curr. Opin. Rheumatol.—1992.—Vol.4—P. 460−482.
- Aufdermaur M. Pathogenesis of square bodies in ankylosing spondylitis. Ann Rheum Dis 1989−48:628−31.
- Baeten D., De Keyeser F., Kruithof E., et al. Systemic review of serious and atypical infections in spondyloarthropathy patients treated with anti-TNF. // Arthritis Rheum. 2002. — 46. — P. 432.
- Baeten D., Demetter P., Kruithof E., et al. Effect of TNFalpha block-ade on synovial histology in spondyloarthropathy. Artr Rheuml. 2000- v.43, suppl., S404.
- Baraliacos X., Listing J., Brandt J., et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 year of continuous treatment with infliximab. Arthr. Res.Ther., 2005, v.7,p.439−444.
- Baraliakos X, Braun J. Anti-TNF-alpha therapy with infliximab in spondyloarthritides.// J. Expert Rev Clin Immunol. 2010 Jan-6(l):9−19.
- Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Sieper J, et al. Radiographic progression in patients with ankylosing spondylitis after 4 years of treatment with the anti-TNF-a antibody infliximab. Rheumatology (Oxford) 2007−46:1450−3.
- Baraliakos X, Listing J, Rudwaleit M, Brandt J, Alten R, Burmester G, et al. Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis. J Rheumatol 2007−34:510−5.
- Baraliakos X, Listing J, Rudwaleit M, Brandt J, Sieper J, Braun J. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor a antibody infliximab. Ann Rheum Dis 2005−64:1462−6.
- Baraliakos X, Listing J, Rudwaleit M, Haibel H, Brandt J, Sieper J, et al. Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis 2007−66:910−5.
- Bardos T, Szabo Z, Czipri M, Vermes C, Tunyogi-Csapo M, Urban RM, et al. A- longitudinal study on an autoimmune* murine model of ankylosing spondylitis. Ann Rheum Dis 2005−64:981−7.
- Barr S.G., Steber W., Kindopp-Bugo K., Martin O.L. Infliximab therapy in the treatment of rheumatoid arthritis in clinical practice. // Ann. Rhem Dis. 2003. -62.-P. 196.
- Bennet N, et al. Severity of baseline magnetic resonance imaging- evident sarcoidosis and HLA-B27status in early inflammatory back pain predict radiographic evident ankylosing spondylitis at eight years (2008) Arthritis Rheum 2008- 58: 3413−3418.
- Beutler B.A. The role of tumor necrosis factor in health and disease // J. Rheumatol. 1999−26(Suppl. 57): 16—21.
- Bollow M et al. (1998) Use of dynamic magnetic resonance imaging to detect sacroiliitis in HLA-B27 positive and negative children with juvenile arthritides. J Rheumatol 25: 556−564
- Bollow M, Hermann KG, Biedermann T, Sieper J, Schontube M, Braun J. Very early spondylarthritis: where the inflammation in the sacroiliac joints starts. Ann Rheum Dis 2005−64:1644−6.
- Bosch van den F., Baeten D., Kruithof E et al. Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor a. Ann. Rheum. Dis., 2001, v.60,suppl.III, iii 33
- Boyer G. S, Lanier A. P, Templin D. W, Bulkow L. Spondyloarthropathy and rheumatoid arthritis in Alaskan Yupik Eskimos // J. Rheumatol. 1990−17(4):489−496.
- Brandt J, Haibel H, Reddig J, et al. Anti-TNF alph a treatment of patients witii. severe anklyosing spondylitis—a one year follow-up abstract. Arthritis Rheum?2000−44(suppl):S403.
- Brandt! Jf Haibel! H^ Sieper J|.Reddia J, Braun J" Infliximab? treatment- of severe ankylosing spondylitis: one-year followup. Arthritis Rheum 2001 -44:2936−7. '
- Brandt J., Haibel H., Reddig J., et al. Anti-TNF alpha treatment of patients with sever ankylosing, spondylitis a one year follow up- //Arthritis Rheum- — 2000.-43.-P. 101.
- Brandt J., Listing J., Alten R. et al. One year results of double-blind placebo controlled- phase-Ill clinical trial-:of infliximab in active ankylosing spondylitis. Arthr.Rheum., 2002, v.46, suppl., S429.
- Brandt J.,. Listing J., Alten R. et al. l’wo-year-follow up data of infliximab therapy in. patients^ with active ankylosing spondylitis: socioeconomic consequences. Arthr.Rheum., 2003, v.48, suppl., S173.
- Braun J- Brandt J, Listing J, Zink A, Alten R, Burmester G, et al. Two year maintenance of efficacy and- safety of infliximab in- the treatment" of ankylosing spondylitis. Ann Rheum Dis 2005−64:229−34.
- Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002- 359: 1187−93.
- Braun J, Davis J, Dougados M et al.- ASAS Working Group. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006−65:316−20.
- Braun J, Golder W, Bollow M, Sieper J, van der Heijde D. Imaging and scoring in ankylosing spondylitis. Clin Exp Rheumatol 2002- 20(6 Suppl 28):S178−84.
- Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M- et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003−62:817−24.
- Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007−369: 1379−90:
- Braun J, Sieper J. Therapy of ankylosing spondylitis and other spondyloartnritides: established medical treatment- anti-TNF-alpha therapy and other novel approaches. Arthritis Res 2002−4:307−21.
- Braun J., Brandt J., Listing J., Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. // Lancet. 2002. — 359. — P. 1187−93.
- Braun J., Deodhar A., Dijkmans B. et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period // Arthritis Rheum. 2008−59(9):1270−1278.
- Braun J., Pham T., Sieper J., et al. International ASAS consensus statement for the use of anti-tumor necrosis factor agents in patients with ankylosing spondylitis. // Ann Rheum Dis. 2003. — 62. — P. 817−824.- 43. — P. 101.
- Braun J., Sieper J. Therapy of ankylosing spondylitis and other spondyloartritides: medical treatment, anti-TNF-a therapy and approaches. // Arthritis Res. 2002. — 4. — P. 307−321.
- Braun J., Sieper J., Breban M. et al. Anti-tumor necrosis factor a therapy for ankylosing spondilitis international experience. Ann. Rheum. Dis., 2002, 61 (Suppl.III), ii51-ii60.
- Braun J., Xiang J., Brandt J. et al. Treatment of spondyloarthropathies with antibodies against tumor necrosis factor-alpha: first clinical and laboratory experiences. Ann.Reum. Dis., 2000, 59, 10−14.
- Braun J., Landewe R, Hermann K.-G. et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab. Arthr.Rheum., 2006, v.54, p. 1646−1652.
- Breban M, Vignon E, Claudepierre P, Devauchelle D, Wendling E, Lepessailes L, et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology (Oxford) 2002−41:1280−5.
- Bredveld F.C., Emery P., Keystone E., et al. Infliximab in active early rheumatoid arthritis. // Ann Rheum Dis. 2004. — 63. — P. 149−155.
- Bretal M., Mera A., Blanco J. et al. Clinical manifestations and evolution of nine cases with Juvenile GEA syndrome.// Proceedings of the XVIII-th ILAR Congress of Rheumatology. Barcelona, 1993. I Rev. Esp. Rheumatol. 1993. -Vol.20, suppl.l. -P.359.
- Brown M.A., Kennedy L.G., Mac Gregor A.I. et al. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA and the environment // Arthritis Rheum. — 1997. — Vol. 40. —P. 1823−1828.
- Brown M.A., Laval S.H., Brophy S., Calin A. Recurrence risk. modelling of the genetic susceptibility to ankylosing spondylitis // Ann. Rheum. Dis. — 2000. — Vol. 59. — № 11. — P. 883−886.
- Brown M.A., Pile K.D., Kennedy L.G. et al. HLA class I associations of ankylosing spondylitis in the white population in the United Kingdom // Ann. Rheum. Dis. — 1996. — Vol. 55. — № 4. — P. 268−270.
- Burgos-Vargas R et al. (2007) Efficacy, safety, and tolerability of infliximab in juvenile-onset spondyloarthropathies (JO-SpA): results of the three-month, randomized, double-blind, placebo-controlled trial phase. Arthritis Rheum 56 (Suppl): S319
- Burgos-Vargas R. A case of childhood-onset ankylosing spondylitis: diagnosis and treatment.// J. Nature Clinical Practice Rheumatology (2009) 5, 5257
- Burgos-Vargas R. Undifferentiated spondyloarthritis: a global perspective. J. Curr Rheumatol Rep. 2007, 9(5):361−366.
- Burgos-Vargas R., Granados-Arriola J. Ankylosing spondylitis and related diseases in the Mexican mestizo. In Spine: State of the art reviews / Ed: by Khan M.A. Philadelphia: Hanley & Belfus Inc., 1990. Vol. 4. N3. P. 665−678.
- Burgos-Vargas R., Petty R.E. Juvenile ankylosing spondylitis // Rheum. Dis. Clin. North Am., 1992. Vol. 18. N1.P. 123−142.
- Burgos-Vargas R., Rojas-Serrano J. Predictor of response to tumor necrosis factor-a blokers in ankylosing spondylitis. J. Rheumatol. 2004, v.31*, p. 16 371 640.
- Burgos-Vargas R., Vazquez-Mellado J. The early clinical recognition of juvenile-onset ankylosing spondylitis and its differentiation from juvenile rheumatoid arthritis. // Arthr. Rheum., 1995. Vol.38. N6. P. 835−844.
- Burgos-Vargas R. Juvenile onset spondyloarthropathies: therapeutic aspects //Ann. Rheum. Dis., 2002. 61 (Suppl. III). III33III39.
- Calin A, et al. Clinical assessment of spondylarthropathies: the bath ankylosing spondylitis instruments. Int J Adv Rheumatol 2007- 5: 66−77.
- Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994−21:2281−5.
- Calin A, Taurog J, editors. The Spondyloarthritides. Oxford, UK: Oxford University Press, 1998:1 -353.
- Calin A. Ankylosing spondylitis. In: Maddison PJ, Isenberg D, Woo P et al., editors. Oxford Textbook of Rheumatology Volume II (2nd edition). Oxford, UK: Oxford University Press, 1998:1058−60.
- Cassidy J.T., Petty R.E. Textbook of pediatric rheumatology. New York, Edinburg, Melbourne, Tokyo, 2001.
- Cassidy JT, Petty RE. Textbook of pediatric rheumatology. 4th ed. Philadelphia: WB Saunders- 2001
- Chen J., Lui C. Sulfasalazin for ankylozing spondylitis.//Cochrane Database Syst Rev 2005- Apr 18(2): CD004800.
- Clegg D.O. The promise of TNF inhibitors in the treatment of ankylosing spondylitis. J. Musculoscel.Med., 2004, v.21, N2(suppl), s.27−33.
- Collantes- Estevez E., Munoz-Villanueva M.C., Canete-Crespilo J.D. et al. Infliximab in refractory spondyloarthropathies: a multicentre 38 week open study. Ann. Rheum.Dis., 2003, v.62, p. 1239−1240.
- Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. // Aliment Pharmacol Ther. 2003 Jan-17(l):75−84
- Dinarello CA, Moldawer L.L. Proinflammatory and anti-inflammatory cytokines in rheumatoid arthritis. A primar for clinicians. Third edition. — 2002. -Amgen Inc. — 351 p.
- Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991−34:1218−27.
- Dreher R., Flaig W., Leitrke D. Treatment of rheumatoid arthritis by intraarticular injections with TNF-alpha blockers. // Arthritis Rheum. 2001. — 44. -P. 45.
- Ebringer A. Ankylosing spondylitis is caused by Klebsiella // Rheum. Dis. Clin. North Am.— 1992.—Vol. 18.—P. 105−121.
- Ebringer A., Baines M., Ptaszynska T. Spondylarthritis, uveitis, HLA-B27 and Klepsiella // GBR-Immunol. Rev. 1985. V.86. — P.101−116.
- Elliot M.J., Maini R.N., Feldmann M=, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor a (cA2) versus placebo in rheumatoid arthritis. I I Lancet. 1994. -344. — P. 1105−1110.
- Elliot M.J., Woo P., Charles P., et al. Suppression of fever and the acute-phase response in a patient with1 juvenile chronic arthritis treated with*monoclonal antibody to tumor necrosis factor-a (cA2). // Br J Rheumatol. 1997. — 36.- P. 589593
- Farr M, Kitas G, Bacon PA. Sulphasalazine in rheumatoid arthritis: combination therapy with D-penicillamine or sodium aurothiomalate.//Clin Rheumatol. 1988 Jun-7(2):242−8
- Fich A, Schwartz J, Braverman D- Zifroni A, RachmilewitzD. Sulfasalazine hepatotoxicity.//Am J Gastroenterol. 1984 May-79(5):401−2
- Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994- 21: 2286−91.
- Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor a. N Engl J Med 2002- 346: 1349−56.
- Grar J.T. Husby G. The epidemiology of ankylosing spondylitis.// Seminars in Arthr. Rheum. 1993.—Vol.22, N5.-319−334.
- Griffoul I., Giraudeau B., Mulleman D. et al. Infliximab for treating axial spondylarthropathy in everyday practice // Joint Bone Spine. — 2009−76(l):39−43.
- Haibel H., Song I.H., Rudwaleit M. et al. Multicenter open-label study with infliximab in active ankylosing spondylitis over 28 week in daily practice // Clin. Exp. Rheumatol. 2008−26(2):247−252.
- Hafner R. Juvenile spondarthritis. Retrospective study of 71 patients. // Monatsschr Kinderheilkd. 1987 Jan- 135(l):41−6.
- Horneff G., Burgos-Vargas R. Juvenile idiopathic arthritis. Subgroup characteristics and comparisons between rheumatoid arthritis-like subgroup and ankylosing spondylitis-like subgroup. // Clin. Exp. Rheumatol. 2009−27(4):131 138.
- HornefT G., Burgos-Vargas R. TNF-a antagonists for the treatment of juvenile-onset spondyloarthritides // Clin. Exp. Rheumatol., 2002. 20 (Suppl.28). S137-S142.
- Inman RD, Maksymowych WP. A Double-blind, Placebo-controlled Trial of Low Dose Infliximab in Ankylosing Spondylitis.// J Rheumatol. 2010 Mar 15.
- Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS): the Bath AS Metrology Index-. J Rheumatol 1994- 21: 1694−8.
- Kalden J.R. Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases // Arthritis Res. 2002−4(Suppl. 2):534—540.
- Keane J., Gershon S., Wise R. Tuberculosis associated with infliximab, a tumor necrosis factor a neutralizing agent. // New Engl J Med. — 2001. — 345. -1098−1104.
- Kelley W.N., Harris E.D., Ruddy S., Sledge C.B. Textbook of Rheumatology // 4-th ed., W.B. Saunders, Philadelphia, 1993. Vol. 1. P. 943−960.
- Khan M.A. Ankylosing spondylitis and geterogeneity of HLA-B27 // Sem. Arthr. Rheum. 1989. V.18. — P.134−141.
- Khan M: A. Ankylosing spondylitis: introductory comments on its. diagnosis and .treatment //Ann. Rheum. Dis., 2002. ?.61. Suppl. III. III3−7
- Khan M: A., van der Linden S. M: Ankylosing spondylitis and' other spondyloarthropathies // Rheum: Dis. Clin. North. Am., 1990: Vol. 16. N3. P- 551 579.
- Khan MA, Mathieu A, Sorrentino R, Akkoc N. The pathogenetic role of HLA-B27 and its subtypes. Autoimmun Rev. 2007 Jan-6(3): 183−9.
- Knight D.M., Trihn H., Le J et al. Construction and initial characterization of mouse-human chimeric monoclonal antibody to tumor necrosis factor-a antibody. //Mol.Immunol. 1993. — 30. — P. 1105−1110.
- Kruithof E., Baeten D, Van der Bosch F. et al. Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodeling of the synovial membrane in spondyloarthropathy. Ann. Rheum. Dis., 2005, v.64, p.529−536.
- Lacomek H.J., Plomann M, Specker C, Schwochau M. Ankylosing spondylitis: an autoimmune disease? // Ann.Rheum.Dis.—1983. Vol.50, N11.— P.776−781.
- Landewe R, Rump B, Van Der Heiide D, Van Der Linden S. Which patients with ankylosing spondylitis should be treated with tumour necrosis factor inhibiting therapy? A survey among Dutch rheumatologists. Ann Rheum Dis 2004- 63: 530−4.
- Lavals H., Timms A., Edvards S. et al. Whole-genome screening in ankylosing spondylitis: evidence of non-MHC genetic-susceptibility loci // Am. J. Hum. Genet. — 2001. — Vol. 68. — P. 918−926.
- Layh-Schmitt G, Colbert RA. The interleukin-23/interleukin-17 axis in spondylarthritis. Curr Opin Rheumatol. 2008 Jul-20(4):392−7.
- Linssen A., Fetkamp T.E.W. B-27 positive diseases versus B-27 negative diseases // Ann. Rheum. Dis. 1988. V.47. — № 5. — P.431−439.
- Lipsky P.E., van der Heijde D.M.F.M, St Clair E.W. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. // N Engl J Med. 2000. -343.-P. 1594−1602
- Lorenz H.M., Kalden J.R. Perspectives for TNFa targeting therapies. // Arthritis Research. 2002. — 4. — P. 17-S24.
- Lories RJ, Derese I, De Bari C, Luyten FP. Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthritis Rheum 2007−56:489−97.
- Mak T.W., Yeh W-H. Signaling for survival and apoptosis in the immune system. // Arthritis Res.2002. 4. — P. 243−252.
- Malleson P.N., Petty R.E. Clinical and therapeutic aspects of juvenile-onset spondyloarthropathies // Curr. Opin. Rheumatol., 1997. V.9. № 4. P. 291−294.
- Markham A., Lamb H.M. Infliximab. A review of its use in the management of rheumatoid arthritis. // Drug. 2000. — 59. — P. 1341−1359.
- Mateo L, Del Blanco J, Juanola X, Valverde J, Roig D. Trauma and seronegative spondyloarthropathy: rapid joint destruction triggered by physical1 injury in HLA-B7. Ann Rheum Dis. 1990 0ct-49(10):821.
- Moll J.M.H. Rheumatology in clinical practice.// Blackwell Scientific Publications, Oxford etc., 1987, 764 p.
- Nicas S.N., Temekonidis T.I., Zikou A.K. et al. Treatment of resistant rheumatoid arthritis by intra-articular infliximab injections: a pilot study. // Ann Rheum Dis. — 2004. — 63. — P. 102−103
- Nissila M., Lehtinen K., Leirisalo-Repo M. et al. Sulphasazine in the treatment of ankylosing spondilitis: a twenty-six-week placebo-controlled clinical trial // Arth. Rheum. — 1998−31:1111−1116.
- Olivieri I, Gherardi S, Bini C, Trippi D, Ciompi ML, Pasero G. Trauma and seronegative spondyloarthropathy: rapid joint destruction in peripheral arthritis triggered by physical injury. Ann Rheum Dis. 1988 Jan-47(l):73−6.
- Pavelka K, Forejtova S, Stolfa J, Chroust K et al. Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA.// Clin Exp Rheumatol. 2009 Nov-Dec-27(6):958−63.
- Pepmuller P.H., Moore T.L. Juvenile spondyloarthropathies // Curr. Opin. Rheumatol., 2000. V. 12. № 4. P. 269−273.
- Pham T et al. An International Study on Starting TNF-blocking agents in Ankylosing Spondylitis (ISSAS). Ann Rheum Dis 2006- 65:1620−1625.
- Pham T, van der Heijde D, Calin A et al. Initiation of biological agents in patients with ankylosing spondylitis: results of a Delphi study by the ASAS Group. Ann Rheum. Dis 2003−62:812−16.
- Pham T, van der Heijde D- Calin’A, Khan MA, van der. Linden S, Bellamy N, et al. Initiation of biological agents in-patients with ankylosing spondylitis: results of a Delphi, study by the ASAS Group. Ann Rheum Dis 2003−62:812−16.
- Pinals RS. Sulfasalazine in the rheumatic disease. // Semin Arthritis Rheum. 1988 May- 17(4):246−59. ~
- Pontikaki I., Gerloni V., Gattinara M. Et al. Effect of anti-tumour necrosis factor alpha antibody (infliximab) on chronic uveitis in juvenile idiopathic (chronic) arthritis. Ann.Rheum.Dis., 2002, v.61, suppl. I, p.382.
- Reed M.R., Taylor A.L. Tumor necrosis factor inhibitors in ankylosing spondylitis // Intern. Med. J. 2008−38(10):781−789.
- Robinson W.P., Van der Linden S.M., Khan M.A. et al. HLA-Bw27 increases susceptibility to ankylosing spondylitis in HLA-B27 + patients // Arthr. Rheum.- 1989. V.32. № 9. — P. 1135−1141.
- Rudwaleit M, et al. The early disease stage in axial spondylarthritis: results from the German spondylarthritis inception cohort. Arthritis Rheum 2009- 60: 717 727.
- Rudwaleit M., Hohler T. Cytokine gene polymorphisms relevant for the spondyloarthropathies // Curr. Opin. Rheumatol. — 2001. — № 13. — P. 250−254.
- Ruperto N., Lovell D.J., Quartier P. et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal, trial>// Lancet. 2008- 372(9636):383−391.
- Scallon B.J., Moore M. Ai, Trihn H. Chimeric anti-TNF-a antibody cA2 binds recombinant transmemrane TNF-a and activates immune effector function. // Cytokine. 1995. — 7. — P. 251−259.
- Schaller J.G. Ankylosing spondylitis of childhood onset // Arthritis Rheum., 1977. Vol. 20, Suppl. P.398−401.
- Schett G, Landewe R, van der Heijde D. Tumour necrosis factor blockers and structural' remodelling in ankylosing spondylitis: what is reality and what is fiction? Ann Rheum Dis 2007−66:709−11.
- Sieper J., Braun J., Rudwaleit M, Boonen A., Zink A. Ankylosing spondilitis: an overview//Ann. Rheum. Dis., 2002, V.61. Suppl. III. 1118−18.
- Schmeling H, Horneff G. Infliximab in two patients with juvenile ankylosing spondylitis,// Rheumatol Int. 2004 May-24(3): 173−6. Epub 2003 Nov 29.
- Smedegard G, Bjork J. Sulphasalazine: mechanism of action in rheumatoid arthritis. //Br J Rheumatol. 1995 Nov-34 Suppl 2:7−15.
- Steinbrocker O., Traeger C.H., Batterman R.C. Therapeutic criteria1 in rheumatoid arthritis. // J.Am. Med. Assoc. 1949.- V.140.- P. 659−662
- Strieter R., Kunkel S., Bone R. Role of Tumor Necrosis Factor-Alpha in Disease States and Inflammation. // Critical Care Medicine. 1993. — 21 — P! 447 463.
- Sulpice M, Deslandre CJ, Quartier P. Efficacy and safety of TNFalpha antagonist therapy in patients with juvenile spondyloarthropathies.//Joint Bone Spine. 2008 Dec 11.—suppl. 32.--.P.7−13.
- Svartz N. The treatment of rheumatic polyarthritis with acid azo compounds./ZRheumatism. 1948 Apr-4(l): 180−5.
- Tam LS, Gu J, Yu D. Pathogenesis of ankylosing spondylitis. Nat Rev Rheumatol. 2010 Jul-6(7):399−405.
- Tomic S., Djilas D, Budimir M. Juvenile ankylosing spondylitis and the joint hypermobility syndrome.// Srpaki Arhiv Za Celokupno Lekarstvo. 1990 — 120 (1−2).-P. 58−60.
- Tracey K.J. et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteriemia.//Nature. 1987. — 330. — P. 662−664.
- Tracey K.J. et al. Shock and tissue injury induced by recombinant human cachectin.// Science. 1986. — 234. — P. 470−474.
- Tse SM, Burgos-Vargas R, Laxer RM. Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy. Arthritis Rheum. 2005−52:2103−8
- Van der Heijde D, Bellamy N, Calin A et al. Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group, J Rheumatol 1997- 24: 2225−9.
- Van der Heijde D, Deoadar A, Geusens P, Han J, Williamson P, Braun J. The effect of infliximab therapy on bone mineral density in patients with ankylosing spondylitis: results from ASSERT. Ann Rheum Dis 2005−64 Suppl 111:319 (FRI0208).
- Van der Heijde D, et al. Assessment in Ankylosing Spondylitis International Working Group/Spondylitis Association of America recommendations for conducting clinical trials in ankylosing spondylitis. Arthritis Rheum 2005−52(2):386−394.
- Van der Heijde D, Landewe R, Deoadar A, Baker D, Han J, Xu W, et al. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment not inhibited with infliximab. Ann Rheum Dis 2007−66 Suppl 11:85−6.
- Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984−27:361−8.
- Van der Linden S., van der Heijde D. Clinical aspects, outcome assessment, and management of ankylosing spondylitis and postenteric reactive arthritis // Curr. Opin. Rheumatol, 2000. V.12. № 4. P. 263−268.
- Vis M., Wolbink J., Soesbergen R., et al. Early changes in bone metabolism in patients with rheumatoid arthritis treated with infliximab.// Ann Rheum Dis. -2002.-61.-P. 51.
- Wallace C.A., Ruperto N., Gannini E. et al. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis // J. Rheumatol. -2004−31(11):2290−2294.
- Wanders A, van der Heijde D, Landewe R, Behier JM, Calin A, Olivieri I, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005−52:1756−65.
- Wijnands MJ, Van’t Hof MA, Van Leeuwen MA, Van Rijswijk MH, Van de Putte LB, Van Riel PL. A prospective analysis of risk factors for the discontinuation of second-line antirheumatic drugs. // Pharm World Sci. 1993 Oct 15−15(5):203−7
- Wong DL, Baker CM. Smiling faces as anchor for pain intensity scales. // Pain. 2001 Jan-89(2−3):295−300.
- Zochling J et al. (2006) ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 65: 442−452
- Zochling J, et al. Current Evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006−65(4):423−432.